Go Therapeutics
Founded Year
2014Stage
Series B | AliveTotal Raised
$25.5MLast Raised
$20.5M | 1 mo agoAbout Go Therapeutics
GO Therapeutics is exploiting aspects of cancer cell biology to develop a class of cancer therapies for previously intractable solid tumors. The company targets O-linked glycoproteins that are specific to cancer cells to develop high-affinity antibodies to cancer-specific targets. The company's antibodies are the basis for a broad array of potent cancer-killing modalities, including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue. Go Therapeutics was founded in 2014 and is based in Natick, Massachusetts.
Go Therapeutics Headquarter Location
22 Strathmore Road
Natick, Massachusetts, 01760,
United States
(800) 978-6543
Expert Collections containing Go Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Go Therapeutics is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Go Therapeutics Patents
Go Therapeutics has filed 7 patents.
The 3 most popular patent topics include:
- Monoclonal antibodies
- Clusters of differentiation
- Experimental cancer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/23/2018 | 11/2/2021 | Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Proteins | Grant |
Application Date | 10/23/2018 |
|---|---|
Grant Date | 11/2/2021 |
Title | |
Related Topics | Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Proteins |
Status | Grant |
Latest Go Therapeutics News
Jun 2, 2022
01-06-2022 Japanese drug major Astellas Pharma’s (TYO: 4503) subsidiary Xyphos Biosciences and Cambridge, Massachusetts-based GO Therapeutics have entered into a strategic research collaboration and license agreement to develop novel immuno-oncology therapeutics. GO is applying new advances in glycoproteomics to develop antibody-based cancer therapeutics that specifically target cancer cells. Xyphos holds a novel and proprietary ACCELTM technology… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
When was Go Therapeutics founded?
Go Therapeutics was founded in 2014.
Where is Go Therapeutics's headquarters?
Go Therapeutics's headquarters is located at 22 Strathmore Road, Natick.
What is Go Therapeutics's latest funding round?
Go Therapeutics's latest funding round is Series B.
How much did Go Therapeutics raise?
Go Therapeutics raised a total of $25.5M.
Who are the investors of Go Therapeutics?
Investors of Go Therapeutics include Astellas Pharma, Roche Holding and Salubris Pharmaceuticals.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.